
ESTA Stock Forecast & Price Target
ESTA Analyst Ratings
Bulls say
Establishment Labs Hldgs is expected to have strong revenue growth, driven by their successful U.S. sales and expanding into international markets. Additionally, their innovative and minimally invasive surgery techniques, along with a strong pipeline of products, are expected to drive future growth. The company's recent beat-and-raise quarter, increased revenue guidance for the full year 2026, and continued momentum in sales support a positive outlook for the stock. While there are risks such as economic downturns and competition, the potential upside drivers include stronger than expected sales and margins. My 12-month price target for this stock is $90 based on an 8.5x multiple applied to the 12-24 month revenue estimate.
Bears say
Establishment Labs Hldgs is facing significant challenges, such as slow sales growth and difficulties in achieving profitability, particularly in the US market. The company's high valuation of 11x EV/sales in 2026 relies heavily on optimistic revenue projections, making it vulnerable to any potential setbacks or delays. With a relatively limited product portfolio and a history of negative earnings, the company's financial health is at risk and may not support long-term sustainable growth.
This aggregate rating is based on analysts' research of Establishment Labs Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ESTA Analyst Forecast & Price Prediction
Start investing in ESTA
Order type
Buy in
Order amount
Est. shares
0 shares